Pro-Dex (PDEX) Stock Analysis & AI Equity Report

Medical - Instruments & Supplies USD Explore free reports

Pro-Dex (PDEX) overview

Pro-Dex (PDEX) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 77.5m and operating profit of USD 13.0m; the year-end share price was 58.55 USD and market capitalisation was USD 187m. Pro-Dex is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Pro-Dex's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 47.6mFY 2026
Share price58.55 USDFY 2026 year end
RevenueUSD 77.5mFY 2026
Operating profitUSD 13.0mFY 2026
Net earningsUSD 13.7mFY 2026
Market capitalisationUSD 187mFY 2026 year end

About Pro-Dex

Pro-Dex designs, develops and manufactures autoclavable, battery-powered and electric multifunction surgical drivers and shavers, primarily for orthopedic, thoracic and craniomaxillofacial procedures. It also provides engineering, quality and regulatory consulting, makes rotary air motors, and manufactures precision machined parts and assemblies for aerospace and defense customers. Its medical devices are sold mainly to original equipment manufacturers and are often developed under exclusive development and supply agreements.

Generate the Pro-Dex report

Pro-Dex is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Pro-Dex and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Pro-Dex

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.